Skip to content Skip to footer
ADVANCING SPASTICITY MANAGEMENT

About Toxnet

Toxnet is a global network of leading experts and specialists in the management of spasticity (including botulinum toxin treatment) that started in 2016. The Toxnet group currently consists of 21 active members with almost 450 years of collective experience (range 13-31 years; average 21.71 years).

They have been faculty members of various symposia and have published a significant amount of scientific literature in the field of spasticity and movement disorders. Their published work includes a consensus on optimization of post-stroke spasticity interventions with Botulinum Toxin, evaluation of spasticity patients using telemedicine, and an opinion paper on the role of physical and rehabilitation medicine in the COVID-19 Pandemic. Toxnet has also published a comprehensive curriculum to standardize education for clinicians in the field of post-stroke spasticity.

Improving outcomes, advancing science.

Why We Do It

The Toxnet group aims to be at the forefront of education, clinical innovation, and research in spasticity, and related disorders, to inspire and guide clinicians for the ultimate benefit of their patients.

Toxnet members are passionate about sharing their knowledge and expertise with other healthcare professionals to improve patient care. Toxnet members are committed to advancing research in this field and sharing their findings with the broader medical community.

To achieve this goal, Toxnet members regularly participate in international congresses and work on a number of projects for publication.

Toxnet Group Structure

The Toxnet group operates within a structured framework that accommodates up to 25 active participants. The group is divided into fluid sub-groups, as required, for specific projects. Since 2023, there have been three distinct sub-groups dedicated to education, research, and clinical innovation. This approach allows for a dynamic and collaborative environment, fostering the pursuit of knowledge and advancement in various domains within the Toxnet group.

Education

Delivery of educational initiatives including publications and symposia

Research

Delivery of research-based projects such as investigator-initiated studies

Clinical innovation

Delivery of value-added projects for the spasticity community

Supported by Merz Therapeutics GmbH

Liability for links
Our site contains links to external websites, over which we have no control. Therefore we cannot accept any responsibility for this external content. The respective provider or operator is always responsible for the contents of any linked site. At the time of linking the linked sites where checked for possible legal violations. At the time of linking illegal contents were not indicated. A permanent control of the linked pages is unreasonable without concrete evidence of violation. Upon notification of violations, we will remove such links immediately.

Award scoring criteria

The following criteria will be judged out of a score of 5; (1 is suboptimal; 2 is adequate; 3 is good; 4 is very good; 5 is excellent)

GENERAL

  • Days per week working in spasticity management
  • Average number of spasticity patients managed per month
  • Environment and clinical team (type of institution, location, size/structure of clinical team, particular patient needs)
  • Role of responsibility in managing patients with spasticity
  • Scientific appointments in spasticity
  • Honours for work undertaken in spasticity

SCHOLARLY

  • Number of research projects investigating relevant aspects of spasticity management
  • Impact of research projects investigating relevant aspects of spasticity management
  • Number of peer-reviewed publications on topic
    Number of presentations of research at international meetings
  • Number of presentations at national conferences
  • Teaching/mentorship of younger injectors
  • h-index

CLINICAL

  • Evidence of development or growth of a spasticity program at the applicant’s practice or institution
  • Breadth of services provided, including medications, toxins, physical interventions, and Intrathecal Baclofen Therapy (ITB)
  • Role of responsibility in managing patients with spasticity

ENDORSEMENT

  • Endorsed by senior peer

In the event of a tie, based on the above scoring criteria, the Toxnet Co-Chairs will make the final decision.